Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocortisone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 3/20 | 0.91 |
| ▸ | HIF1A | Q16665 | 12/20 | 0.91 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.91 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.91 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.91 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.91 |
| ▸ | PGR | P06401 | 3/20 | 0.91 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.91 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.91 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.91 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.91 |
| ▸ | SHBG | P04278 | 2/20 | 0.91 |
| ▸ | MAPT | P10636 | 2/20 | 0.91 |
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | AR | P10275 | 1/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.72 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocortisone SCHEMBL221483 | 1.00 | HIF1A (0.91) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL3105442 | 0.99 | HIF1A (0.89) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL2881419 | 0.99 | HIF1A (0.89) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL28908729 | 0.96 | HIF1A (0.86) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL4697 | 0.96 | HIF1A (0.86) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL3999007 | 0.95 | HIF1A (0.96) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL24900238 | 0.95 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL1688689 | 0.95 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL5699764 | 0.95 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL143923 | 0.95 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1758 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118308292-A | Cytokine-free adjuvant, in particular for in vitro fertilisation or for cell culture media of follicles, male germ cells or embryos | 派乔易股份有限公司 | 2024-07-09 | — | — | CN | claimed |
| EP-4045015-B1 | NOVEL HYDROCORTISONE HEMISUCCINATE LYOPHILISATE | AGUETTANT LAB (FR) | 2024-03-06 | — | — | EP | claimed |
| CN-117512012-A | Immortalized human scleral fibroblast and construction method thereof | 首都医科大学附属北京同仁医院 | 2024-02-06 | — | — | CN | claimed |
| US-20220362157-A1 | NEW HYDROCORTISONE HEMISUCCINATE LYOPHILIZATE | LABORATOIRE AGUETTANT (FR) | 2022-11-17 | — | — | US | claimed |
| EP-4045015-A1 | NOVEL HYDROCORTISONE HEMISUCCINATE LYOPHILISATE | Laboratoire Aguettant (FR) | 2022-08-24 | — | — | EP | claimed |
| CN-114585351-A | Novel freeze-dried hydrocortisone hemisuccinate | 阿奎坦实验室 | 2022-06-03 | — | — | CN | claimed |
| US-20220112267-A1 | PRODUCE AND ISOLATE AND/OR EXTRACT COLLAGEN AND/OR GELATIN FROM ANIMAL CELL LINES AND/OR TISSUE EXPLANTS | Jellatech, Inc. (US) | 2022-04-14 | — | — | US | claimed |
| CN-114288249-A | Nano immune regulation medicine for regulating proportion of Treg/Th17 cells in focus microenvironment and preparation method and application thereof | 中山大学附属第一医院 | 2022-04-08 | — | — | CN | claimed |
| US-20210330611-A1 | THERAPY FOR NEUROLOGICAL DISEASES/DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-28 | — | — | US | claimed |
| CN-113528426-A | Method for culturing fibroblast from autologous skin | 江苏省人民医院（南京医科大学第一附属医院） | 2021-10-22 | — | — | CN | claimed |
| US-20020013305-A1 | AQUEOUS SOLVENT FOR CORTICOSTEROIDS | BLANSETT PHARMACAL CO., INC. | 2002-01-31 | — | — | US | claimed |
| WO-2001098291-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS | ATHEROGENICS, INC. (US) | 2001-12-27 | — | — | WO | claimed |
| CN-1276246-A | Process for preparing medicines with no or low loxic by-effect on gastrointestinal system | WANG XIAO (CN) | 2000-12-13 | — | — | CN | claimed |
| EP-0972828-A1 | Process for the in vitro replication of HCV | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2000-01-19 | — | — | EP | claimed |
| WO-1999067362-A1 | PROCESS FOR THE IN VITRO REPLICATION OF HCV | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE I.N.S.E.R.M. (FR) | 1999-12-29 | — | — | WO | claimed |
| US-5173302-A | 2-acrylamido-2-methyl propanesulfonic acid copolymer, ethylene /propylene oxide derivative humectant, crosslinking monomer, initiator | MEDTRONIC, INC. (US) | 1992-12-22 | — | — | US | claimed |
| EP-0503009-A1 | HYDROPHILIC PRESSURE SENSITIVE ADHESIVE FOR TOPICAL ADMINISTRATION OF HYDROPHOBIC DRUGS | LUDLOW CORPORATION (US) | 1992-09-16 | — | — | EP | claimed |
| US-5112757-A | METHOD FOR OBTAINING HUMAN HEPATOCYTE CULTURES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE (FR) | 1992-05-12 | — | — | US | claimed |
| WO-1992005810-A1 | HYDROPHILIC PRESSURE SENSITIVE ADHESIVE FOR TOPICAL ADMINISTRATION OF HYDROPHOBIC DRUGS | MEDTRONIC, INC. (US) | 1992-04-16 | — | — | WO | claimed |
| EP-0143809-B1 | METHOD FOR OBTAINING HUMAN HEPATOCYTES CULTURES, CULTURES OBTAINED THEREBY AND BIOLOGICAL AND BIOCHEMICAL APPLICATIONS THEREOF | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1989-01-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220362157-A1 | NEW HYDROCORTISONE HEMISUCCINATE LYOPHILIZATE | CRH, SERPINA6, SORD | NR3C1 17/4885HIF1A 348/4885HSD17B10 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.